Posted by Michael Wonder on 16 Apr 2026
ICER releases white paper on accelerated approval pathway for prescription drugs
16 April 2026 - The ICER, in collaboration with Verdant Research, has published a new white paper today that examines the evolution – and perception – of the FDA accelerated approval pathway.
The paper, titled “Strengthening the FDA’s Accelerated Approval Pathway: Progress and Unfinished Business,” reviews recent regulatory and market changes and identifies several policies that could be adopted to further improve the pathway.
